In light of their findings illustrating the involvement of PIM kinase in constructing functional 26S proteasomes, using a PIM inhibitor with established anti-cancer drugs could offer therapeutic advantages for a subgroup of GBM patients characterized by high expression of MDM2 and wild-type p53 status [65]. Here, MDM2 is linked to glioblastoma.